[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse JAK3

Summary
SymbolJAK3
NameJanus kinase 3
Aliases L-JAK; JAKL; LJAK; JAK3_HUMAN; JAK-3; tyrosine-protein kinase JAK3; leukocyte Janus kinase; JAK-3_HUMAN; Jan ......
Chromosomal Location19p13-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Endomembrane system Peripheral membrane protein Cytoplasm
Domain PF07714 Protein tyrosine kinase
Function

Non-receptor tyrosine kinase involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins. Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, upon IL2R activation by IL2, JAK1 and JAK3 molecules bind to IL2R beta (IL2RB) and gamma chain (IL2RG) subunits inducing the tyrosine phosphorylation of both receptor subunits on their cytoplasmic domain. Then, STAT5A AND STAT5B are recruited, phosphorylated and activated by JAK1 and JAK3. Once activated, dimerized STAT5 translocates to the nucleus and promotes the transcription of specific target genes in a cytokine-specific fashion.

> Gene Ontology
 
Biological Process GO:0001776 leukocyte homeostasis
GO:0001818 negative regulation of cytokine production
GO:0002250 adaptive immune response
GO:0002260 lymphocyte homeostasis
GO:0002263 cell activation involved in immune response
GO:0002285 lymphocyte activation involved in immune response
GO:0002286 T cell activation involved in immune response
GO:0002287 alpha-beta T cell activation involved in immune response
GO:0002292 T cell differentiation involved in immune response
GO:0002293 alpha-beta T cell differentiation involved in immune response
GO:0002294 CD4-positive, alpha-beta T cell differentiation involved in immune response
GO:0002366 leukocyte activation involved in immune response
GO:0002367 cytokine production involved in immune response
GO:0002371 dendritic cell cytokine production
GO:0002440 production of molecular mediator of immune response
GO:0002443 leukocyte mediated immunity
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002521 leukocyte differentiation
GO:0002683 negative regulation of immune system process
GO:0002694 regulation of leukocyte activation
GO:0002695 negative regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002698 negative regulation of immune effector process
GO:0002700 regulation of production of molecular mediator of immune response
GO:0002701 negative regulation of production of molecular mediator of immune response
GO:0002703 regulation of leukocyte mediated immunity
GO:0002704 negative regulation of leukocyte mediated immunity
GO:0002718 regulation of cytokine production involved in immune response
GO:0002719 negative regulation of cytokine production involved in immune response
GO:0002730 regulation of dendritic cell cytokine production
GO:0002731 negative regulation of dendritic cell cytokine production
GO:0002819 regulation of adaptive immune response
GO:0002820 negative regulation of adaptive immune response
GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002823 negative regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002825 regulation of T-helper 1 type immune response
GO:0002826 negative regulation of T-helper 1 type immune response
GO:0006606 protein import into nucleus
GO:0006913 nucleocytoplasmic transport
GO:0007159 leukocyte cell-cell adhesion
GO:0007162 negative regulation of cell adhesion
GO:0007259 JAK-STAT cascade
GO:0007260 tyrosine phosphorylation of STAT protein
GO:0007262 STAT protein import into nucleus
GO:0009100 glycoprotein metabolic process
GO:0009101 glycoprotein biosynthetic process
GO:0010559 regulation of glycoprotein biosynthetic process
GO:0010561 negative regulation of glycoprotein biosynthetic process
GO:0017038 protein import
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0022407 regulation of cell-cell adhesion
GO:0022408 negative regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0030098 lymphocyte differentiation
GO:0030183 B cell differentiation
GO:0030217 T cell differentiation
GO:0032613 interleukin-10 production
GO:0032615 interleukin-12 production
GO:0032653 regulation of interleukin-10 production
GO:0032655 regulation of interleukin-12 production
GO:0032693 negative regulation of interleukin-10 production
GO:0032695 negative regulation of interleukin-12 production
GO:0032943 mononuclear cell proliferation
GO:0032944 regulation of mononuclear cell proliferation
GO:0032946 positive regulation of mononuclear cell proliferation
GO:0034504 protein localization to nucleus
GO:0035710 CD4-positive, alpha-beta T cell activation
GO:0035771 interleukin-4-mediated signaling pathway
GO:0038083 peptidyl-tyrosine autophosphorylation
GO:0042088 T-helper 1 type immune response
GO:0042093 T-helper cell differentiation
GO:0042098 T cell proliferation
GO:0042102 positive regulation of T cell proliferation
GO:0042110 T cell activation
GO:0042113 B cell activation
GO:0042129 regulation of T cell proliferation
GO:0043029 T cell homeostasis
GO:0043367 CD4-positive, alpha-beta T cell differentiation
GO:0043370 regulation of CD4-positive, alpha-beta T cell differentiation
GO:0043371 negative regulation of CD4-positive, alpha-beta T cell differentiation
GO:0043434 response to peptide hormone
GO:0044744 protein targeting to nucleus
GO:0045063 T-helper 1 cell differentiation
GO:0045210 FasL biosynthetic process
GO:0045219 regulation of FasL biosynthetic process
GO:0045221 negative regulation of FasL biosynthetic process
GO:0045580 regulation of T cell differentiation
GO:0045581 negative regulation of T cell differentiation
GO:0045619 regulation of lymphocyte differentiation
GO:0045620 negative regulation of lymphocyte differentiation
GO:0045622 regulation of T-helper cell differentiation
GO:0045623 negative regulation of T-helper cell differentiation
GO:0045625 regulation of T-helper 1 cell differentiation
GO:0045626 negative regulation of T-helper 1 cell differentiation
GO:0045785 positive regulation of cell adhesion
GO:0046631 alpha-beta T cell activation
GO:0046632 alpha-beta T cell differentiation
GO:0046634 regulation of alpha-beta T cell activation
GO:0046636 negative regulation of alpha-beta T cell activation
GO:0046637 regulation of alpha-beta T cell differentiation
GO:0046639 negative regulation of alpha-beta T cell differentiation
GO:0046651 lymphocyte proliferation
GO:0046777 protein autophosphorylation
GO:0048872 homeostasis of number of cells
GO:0050670 regulation of lymphocyte proliferation
GO:0050671 positive regulation of lymphocyte proliferation
GO:0050777 negative regulation of immune response
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0050866 negative regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050868 negative regulation of T cell activation
GO:0050870 positive regulation of T cell activation
GO:0051169 nuclear transport
GO:0051170 nuclear import
GO:0051249 regulation of lymphocyte activation
GO:0051250 negative regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0060396 growth hormone receptor signaling pathway
GO:0060397 JAK-STAT cascade involved in growth hormone signaling pathway
GO:0060416 response to growth hormone
GO:0070227 lymphocyte apoptotic process
GO:0070228 regulation of lymphocyte apoptotic process
GO:0070229 negative regulation of lymphocyte apoptotic process
GO:0070231 T cell apoptotic process
GO:0070232 regulation of T cell apoptotic process
GO:0070233 negative regulation of T cell apoptotic process
GO:0070242 thymocyte apoptotic process
GO:0070243 regulation of thymocyte apoptotic process
GO:0070244 negative regulation of thymocyte apoptotic process
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070661 leukocyte proliferation
GO:0070663 regulation of leukocyte proliferation
GO:0070665 positive regulation of leukocyte proliferation
GO:0070669 response to interleukin-2
GO:0070670 response to interleukin-4
GO:0070672 response to interleukin-15
GO:0071104 response to interleukin-9
GO:0071353 cellular response to interleukin-4
GO:0071375 cellular response to peptide hormone stimulus
GO:0071378 cellular response to growth hormone stimulus
GO:0071417 cellular response to organonitrogen compound
GO:0071593 lymphocyte aggregation
GO:0071887 leukocyte apoptotic process
GO:0097696 STAT cascade
GO:1901652 response to peptide
GO:1901653 cellular response to peptide
GO:1902105 regulation of leukocyte differentiation
GO:1902106 negative regulation of leukocyte differentiation
GO:1902593 single-organism nuclear import
GO:1903018 regulation of glycoprotein metabolic process
GO:1903019 negative regulation of glycoprotein metabolic process
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903038 negative regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
GO:1903706 regulation of hemopoiesis
GO:1903707 negative regulation of hemopoiesis
GO:2000106 regulation of leukocyte apoptotic process
GO:2000107 negative regulation of leukocyte apoptotic process
GO:2000514 regulation of CD4-positive, alpha-beta T cell activation
GO:2000515 negative regulation of CD4-positive, alpha-beta T cell activation
Molecular Function GO:0004713 protein tyrosine kinase activity
GO:0004715 non-membrane spanning protein tyrosine kinase activity
GO:0005085 guanyl-nucleotide exchange factor activity
GO:0005088 Ras guanyl-nucleotide exchange factor activity
GO:0019902 phosphatase binding
GO:0019903 protein phosphatase binding
Cellular Component GO:0009898 cytoplasmic side of plasma membrane
GO:0019897 extrinsic component of plasma membrane
GO:0019898 extrinsic component of membrane
GO:0031234 extrinsic component of cytoplasmic side of plasma membrane
GO:0098552 side of membrane
GO:0098562 cytoplasmic side of membrane
> KEGG and Reactome Pathway
 
KEGG hsa04062 Chemokine signaling pathway
hsa04151 PI3K-Akt signaling pathway
hsa04550 Signaling pathways regulating pluripotency of stem cells
hsa04630 Jak-STAT signaling pathway
Reactome R-HSA-170984: ARMS-mediated activation
R-HSA-422475: Axon guidance
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-1266738: Developmental Biology
R-HSA-186763: Downstream signal transduction
R-HSA-2871796: FCERI mediated MAPK activation
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-170968: Frs2-mediated activation
R-HSA-392451: G beta
R-HSA-397795: G-protein beta
R-HSA-388396: GPCR downstream signaling
R-HSA-114604: GPVI-mediated activation cascade
R-HSA-179812: GRB2 events in EGFR signaling
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-109582: Hemostasis
R-HSA-2428924: IGF1R signaling cascade
R-HSA-112399: IRS-mediated signalling
R-HSA-2428928: IRS-related events triggered by IGF1R
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-74751: Insulin receptor signalling cascade
R-HSA-912526: Interleukin receptor SHC signaling
R-HSA-451927: Interleukin-2 signaling
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-1266695: Interleukin-7 signaling
R-HSA-5683057: MAPK family signaling cascades
R-HSA-5684996: MAPK1/MAPK3 signaling
R-HSA-375165: NCAM signaling for neurite out-growth
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-169893: Prolonged ERK activation events
R-HSA-5673001: RAF/MAP kinase cascade
R-HSA-8853659: RET signaling
R-HSA-180336: SHC1 events in EGFR signaling
R-HSA-112412: SOS-mediated signalling
R-HSA-162582: Signal Transduction
R-HSA-177929: Signaling by EGFR
R-HSA-372790: Signaling by GPCR
R-HSA-74752: Signaling by Insulin receptor
R-HSA-449147: Signaling by Interleukins
R-HSA-2586552: Signaling by Leptin
R-HSA-186797: Signaling by PDGF
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
R-HSA-194138: Signaling by VEGF
R-HSA-166520: Signalling by NGF
R-HSA-187687: Signalling to ERKs
R-HSA-167044: Signalling to RAS
R-HSA-187706: Signalling to p38 via RIT and RIN
R-HSA-4420097: VEGFA-VEGFR2 Pathway
R-HSA-5218921: VEGFR2 mediated cell proliferation
Summary
SymbolJAK3
NameJanus kinase 3
Aliases L-JAK; JAKL; LJAK; JAK3_HUMAN; JAK-3; tyrosine-protein kinase JAK3; leukocyte Janus kinase; JAK-3_HUMAN; Jan ......
Chromosomal Location19p13-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between JAK3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between JAK3 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26014096Lung CarcinomaInhibit immunity (T cell function)We discovered activating somatic and germline amino acid variants in JAK3 that promoted PD-L1 induction in lung cancer cells and in the tumor immune microenvironment.
22588558Nasopharyngeal CarcinomaInhibit immunityIn epithelial cells, LMP1 up-regulated HLA class I APM. This effect could be counteracted by c-Myc, which itself was up-regulated by LMP1 apparently through IL6 induction and Jak3/STAT3 activation. These findings raise the possibility that c-Myc activation in nasopharyngeal carcinoma (NPC) might antagonise the effect of LMP1 on HLA class I expression thus contributing to immune escape of tumour cells.
18281483Primary Cutaneous T-Cell Non-Hodgkin LymphomaInhibit immunity (T and NK cell function); immunotherapy targetThey also suggest two novel therapeutic approaches to CTCL and, possibly, other CD4+ T-cell lymphomas: inhibition of the Jak1/Jak3 kinase complex and, given the known strong immunostimulatory properties of IL-21 on CD8+ T, natural killer, and B cells, application of this cytokine to boost an immune response against malignant CD4+ T cells.
25125657melanomaPromote immunityMechanistically, in CD8(+) T cells, exposure to CCDC134 promoted cell proliferation through the JAK3-STAT5 pathway, a classic feature of many cytokines of the common gamma-chain (gamma(c)) cytokine receptor family.
Summary
SymbolJAK3
NameJanus kinase 3
Aliases L-JAK; JAKL; LJAK; JAK3_HUMAN; JAK-3; tyrosine-protein kinase JAK3; leukocyte Janus kinase; JAK-3_HUMAN; Jan ......
Chromosomal Location19p13-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of JAK3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolJAK3
NameJanus kinase 3
Aliases L-JAK; JAKL; LJAK; JAK3_HUMAN; JAK-3; tyrosine-protein kinase JAK3; leukocyte Janus kinase; JAK-3_HUMAN; Jan ......
Chromosomal Location19p13-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of JAK3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.4250.405
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.0740.388
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.040.971
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.5140.257
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2690.897
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.830.766
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.8580.0943
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.0280.433
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.7960.547
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.40.207
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.3240.419
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1710.293
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of JAK3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.42.74.70.294
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.43.440.587
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolJAK3
NameJanus kinase 3
Aliases L-JAK; JAKL; LJAK; JAK3_HUMAN; JAK-3; tyrosine-protein kinase JAK3; leukocyte Janus kinase; JAK-3_HUMAN; Jan ......
Chromosomal Location19p13-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of JAK3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolJAK3
NameJanus kinase 3
Aliases L-JAK; JAKL; LJAK; JAK3_HUMAN; JAK-3; tyrosine-protein kinase JAK3; leukocyte Janus kinase; JAK-3_HUMAN; Jan ......
Chromosomal Location19p13-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of JAK3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by JAK3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolJAK3
NameJanus kinase 3
Aliases L-JAK; JAKL; LJAK; JAK3_HUMAN; JAK-3; tyrosine-protein kinase JAK3; leukocyte Janus kinase; JAK-3_HUMAN; Jan ......
Chromosomal Location19p13-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of JAK3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolJAK3
NameJanus kinase 3
Aliases L-JAK; JAKL; LJAK; JAK3_HUMAN; JAK-3; tyrosine-protein kinase JAK3; leukocyte Janus kinase; JAK-3_HUMAN; Jan ......
Chromosomal Location19p13-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of JAK3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolJAK3
NameJanus kinase 3
Aliases L-JAK; JAKL; LJAK; JAK3_HUMAN; JAK-3; tyrosine-protein kinase JAK3; leukocyte Janus kinase; JAK-3_HUMAN; Jan ......
Chromosomal Location19p13-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between JAK3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolJAK3
NameJanus kinase 3
Aliases L-JAK; JAKL; LJAK; JAK3_HUMAN; JAK-3; tyrosine-protein kinase JAK3; leukocyte Janus kinase; JAK-3_HUMAN; Jan ......
Chromosomal Location19p13-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting JAK3 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting JAK3.
ID Name Drug Type Targets #Targets
DB047162-(1,1-DIMETHYLETHYL)9-FLUORO-3,6-DIHYDRO-7H-BENZ[H]-IMIDAZ[4,5-F]ISOQUINOLIN-7-ONESmall MoleculeDAPK3, JAK1, JAK2, JAK3, TYK25
DB08895TofacitinibSmall MoleculeJAK1, JAK2, JAK3, TYK24
DB11817BaricitinibSmall MoleculeJAK1, JAK2, JAK3, PTK2B4